Lintuzumab-Ac225 in Older Acute Myeloid Leukemia (AML) Patients
Public ClinicalTrials.gov record NCT02575963. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase I/II Study of Lintuzumab-Ac225 in Older Patients With Untreated Acute Myeloid Leukemia
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The study is a multicenter, open label Phase I/II trial. 1. Establish the MTD of fractionated doses of Lintuzumab-Ac225 in combination with low dose cytosine arabinoside (Low Dose Ara-C, LDAC) (Phase 1 portion) 2. Determine the response rate (CR + CRp + CRi) to fractionated doses of Lintuzumab-Ac225 alone (Phase 2 portion)
Study identification
- NCT ID
- NCT02575963
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 40 participants
Conditions and interventions
Conditions
Interventions
- Cytarabine (Phase 1 only) Drug
- Lintuzumab-Ac225 Biological
- Furosemide (Phase 1 only) Drug
- Spironolactone Drug
Drug · Biological
Eligibility (public fields only)
- Age range
- 60 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 2012 (Type not available)
- Primary completion
- Nov 2018 (Actual)
- Completion
- May 2020 (Actual)
- Last update posted
- Jul 20, 2023
2012 – 2020
United States locations
- U.S. sites
- 16
- U.S. states
- 12
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| UCLA Medical Center, Division of Hematology/Oncology | Los Angeles | California | 90095 | — |
| University of Kentucky, Markey Cancer Center | Lexington | Kentucky | 40536 | — |
| University of Louisville, James Graham Brown Cancer Center | Louisville | Kentucky | 40202 | — |
| Ochsner Medical Center, The Gayle and Tom Benson Cancer Center | New Orleans | Louisiana | 70121 | — |
| Mayo Clinic | Rochester | Minnesota | 55905 | — |
| Weill Medical College of Cornell University | New York | New York | 10021 | — |
| Columbia University Medical, Herbert Irving Comprehensive Cancer Center | New York | New York | 10032 | — |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | — |
| Duke Cancer Center | Durham | North Carolina | 27705 | — |
| University of Pennsylvania, Perelman Center for Advanced Medicine | Philadelphia | Pennsylvania | 19104 | — |
| St. Francis Cancer Center | Greenville | South Carolina | 29607 | — |
| Baylor Scott and White Research Institute, Charles A. Sammons Cancer Center | Dallas | Texas | 75246 | — |
| Swedish Cancer Institute, Center for Blood Disorders and Stem Cell Transplantation | Seattle | Washington | 98104 | — |
| Fred Hutchinson Cancer Research Center | Seattle | Washington | 98109 | — |
| West Virginia University, Mary Babb Randolph Cancer Center | Morgantown | West Virginia | 26506 | — |
| Medical College of Wisconsin Cancer Center | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02575963, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 20, 2023 · Synced Oct 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02575963 live on ClinicalTrials.gov.